Nonmyeloablative hematopoietic cell transplant for treatment of immune deficiency

Hematopoietic stem cell transplantation (HCT) may offer the only curative therapy for certain life-threatening immune deficiency disorders. Conventional HCT poses a risk to patients for severe morbidity, mortality, and late sequelae resulting from myeloablative preparative regimens. This review summarizes the development of nonmyeloablative regimens that have the potential to reduce both short-and long-term risks of HCT. Results of NM-HCT in a small number of patients indicate that this procedure may play an important role in treating life-threatening immune deficiencies.

[1]  R. Storb,et al.  Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. , 2001, Blood.

[2]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[3]  S. Holland,et al.  Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. , 2001, The New England journal of medicine.

[4]  J. Ziegler,et al.  Reduced memory B‐cell populations in boys with B‐cell dysfunction after bone marrow transplantation for X‐linked severe combined immunodeficiency , 2001, British journal of haematology.

[5]  P. Thall,et al.  Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. , 2001, Blood.

[6]  W. Sanger,et al.  Full hematopoietic engraftment after allogeneic bone marrow transplantation without cytoreduction in a child with severe combined immunodeficiency. , 2001, Blood.

[7]  N. Schmitz,et al.  Higher than expected transplant-related mortality and relapse following nonmyeloablative stem cell transplantation for lymphoma adversely effects progression free survival. , 2000 .

[8]  G. Mieli-Vergani,et al.  Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. , 2000, Blood.

[9]  S. Heimfeld,et al.  Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. , 2000, Blood.

[10]  A. Fischer,et al.  Long-term chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: A single-center study of 22 patients. , 1999, Blood.

[11]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. , 1999, Blood.

[12]  S. Saidman,et al.  Mixed lymphohaemopoietic chimerism and graft-ver suslymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation , 1999, The Lancet.

[13]  J. Roberts,et al.  Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. , 1999, The New England journal of medicine.

[14]  A. Nagler,et al.  Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease , 1999, Bone Marrow Transplantation.

[15]  N. Ueno,et al.  Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[17]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[18]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.

[19]  A. Filipovich.  STEM CELL TRANSPLANTATION FROM UNRELATED DONORS FOR CORRECTION OF PRIMARY IMMUNODEFICIENCIES , 1996, Radiologic Clinics of North America.

[20]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[21]  M. V. van Tol,et al.  Relationship between patterns of engraftment in peripheral blood and immune reconstitution after allogeneic bone marrow transplantation for (severe) combined immunodeficiency. , 1994, Blood.

[22]  W. Friedrich,et al.  Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: a report from the European Group for BMT and the European Group for Immunodeficiency , 1994 .

[23]  W. Friedrich,et al.  Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: a report from the European Group for BMT and the European Group for Immunodeficiency. , 1994, Blood.

[24]  A. Filipovich.  Bone marrow transplantation from unrelated donors for congenital immunodeficiencies. , 1993, Bone marrow transplantation.

[25]  B. Blazar,et al.  Unrelated donor bone marrow transplantation for correction of lethal congenital immunodeficiencies. , 1992, Blood.

[26]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.

[27]  T. Small,et al.  The use of HLA-non-identical T-cell-depleted marrow transplants for correction of severe combined immunodeficiency disease. , 1989, Immunodeficiency reviews.

[28]  W. Friedrich,et al.  Transient hemopoietic stem cell engraftment after transplantation of HLA-haploidentical, T-cell-depleted bone marrow. , 1987, Transplantation.

[29]  A. Fischer,et al.  BONE-MARROW TRANSPLANTATION FOR IMMUNODEFICIENCIES AND OSTEOPETROSIS: EUROPEAN SURVEY, 1968-1985 , 1986, The Lancet.

[30]  H. Deeg,et al.  Marrow Transplantation in Thirty "Untransfused" Patients with Severe Aplastic Anemia , 1980, Annals of Internal Medicine.

[31]  P. Neiman,et al.  Allogeneic marrow grafting for treatment of aplastic anemia. , 1974, Blood.

[32]  J Andrews,et al.  Letter: Clinical trials with vitamin C. , 1974, Lancet.